InflaRx (IFRX) Other Non-Current Liabilities (2016 - 2026)
InflaRx (IFRX) posted Other Non-Current Liabilities of $454176.7 for Q1 2026, up 8.7% sequentially from $417838.1 in Q4 2025, and up 24.13% YoY from $365886.4 in Q1 2025.
InflaRx (IFRX) Other Non-Current Liabilities (2016 - 2026) Analysis & Trends
InflaRx has reported Other Non-Current Liabilities for 11 years, with the latest figure at $454176.7 in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 24.13% year-over-year to $454176.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $454176.7 (up 24.13% YoY) and the FY2025 annual result came in at $405550.2, up 916.08% from the prior year.
- Other Non-Current Liabilities climbed to $454176.7 in Q1 2026 per IFRX's latest filing, from $417838.1 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $3.3 million in Q3 2023 and troughed at $39406.6 in Q4 2024.
- A 5-year average of $754809.9 and a median of $259491.7 in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities jumped 8150.99% in 2023, then sank 98.73% in 2024.
- Over 5 years, Other Non-Current Liabilities stood at $150596.7 in 2022, then soared by 1961.74% to $3.1 million in 2023, then sank by 98.73% to $39406.6 in 2024, then soared by 960.33% to $417838.1 in 2025, then advanced by 8.7% to $454176.7 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $454176.7, $417838.1, and $399353.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 454,176.73 |
| Dec 31, 2025 | 417,838.08 |
| Sep 30, 2025 | 399,353.90 |
| Jun 30, 2025 | 409,331.34 |
| Mar 31, 2025 | 365,886.43 |
| Dec 31, 2024 | 39,406.59 |
| Sep 30, 2024 | 259,491.70 |
| Jun 30, 2024 | 187,728.43 |
| Mar 31, 2024 | 3.20 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Sep 30, 2023 | 3.32 Mn |
| Jun 30, 2023 | 226,551.81 |
| Mar 31, 2023 | 175,592.28 |
| Dec 31, 2022 | 150,596.67 |
| Sep 30, 2022 | 40,208.97 |
| Jun 30, 2022 | 40,263.25 |
| Mar 31, 2022 | 39,986.65 |
| Dec 31, 2021 | 158,103.65 |
| Sep 30, 2021 | 153,385.18 |
| Jun 30, 2021 | 40,933.19 |